Genetic background controls tumor development in Pten-deficient mice

Dan Freeman, Ralf Lesche, Nathalie Kertesz, Shungyou Wang, Gang Li, Jing Gao, Matthias Groszer, Hilda Martinez-Diaz, Nora Rozengurt, George Thomas, Xin Liu, Hong Wu

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

PTEN is one of the most frequently mutated tumor suppressor genes in human cancers. Germ line mutations of PTEN have been detected in three rare autosomal-dominant disorders. However, identical mutations in the PTEN gene may lead to different symptoms that have traditionally been described as different disorders, such as Cowden disease, Lhermitte-Duclos disease, and Bannayan-Zonana syndromes. This lack of genotype-phenotype correlation prompted us to directly test the possible effects of genetic background or modifier genes on PTEN-controlled tumorigenesis using genetically engineered mouse models. In this study, we generated two animal models in which either exon 5 (Pten Δ5) or promoter to exon 3 (Pten-) of the murine Pten gene were deleted and compared phenotypes associated with individual mutations on two genetic backgrounds. We found that the onset and spectrum of tumor formation depend significantly on the genetic background but less on the type of mutation generated. Our results suggest that PTEN plays a critical role in cancer development, and genetic background may influence the onset, the spectrum, and the progression of tumorigenesis caused by Pten mutation.

Original languageEnglish (US)
Pages (from-to)6492-6496
Number of pages5
JournalCancer Research
Volume66
Issue number13
DOIs
StatePublished - Jul 1 2006
Externally publishedYes

Fingerprint

Multiple Hamartoma Syndrome
Exons
Mutation
Neoplasms
Carcinogenesis
Modifier Genes
Germ-Line Mutation
Genetic Association Studies
Tumor Suppressor Genes
Genes
Animal Models
Phenotype
Genetic Background

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Freeman, D., Lesche, R., Kertesz, N., Wang, S., Li, G., Gao, J., ... Wu, H. (2006). Genetic background controls tumor development in Pten-deficient mice. Cancer Research, 66(13), 6492-6496. https://doi.org/10.1158/0008-5472.CAN-05-4143

Genetic background controls tumor development in Pten-deficient mice. / Freeman, Dan; Lesche, Ralf; Kertesz, Nathalie; Wang, Shungyou; Li, Gang; Gao, Jing; Groszer, Matthias; Martinez-Diaz, Hilda; Rozengurt, Nora; Thomas, George; Liu, Xin; Wu, Hong.

In: Cancer Research, Vol. 66, No. 13, 01.07.2006, p. 6492-6496.

Research output: Contribution to journalArticle

Freeman, D, Lesche, R, Kertesz, N, Wang, S, Li, G, Gao, J, Groszer, M, Martinez-Diaz, H, Rozengurt, N, Thomas, G, Liu, X & Wu, H 2006, 'Genetic background controls tumor development in Pten-deficient mice', Cancer Research, vol. 66, no. 13, pp. 6492-6496. https://doi.org/10.1158/0008-5472.CAN-05-4143
Freeman D, Lesche R, Kertesz N, Wang S, Li G, Gao J et al. Genetic background controls tumor development in Pten-deficient mice. Cancer Research. 2006 Jul 1;66(13):6492-6496. https://doi.org/10.1158/0008-5472.CAN-05-4143
Freeman, Dan ; Lesche, Ralf ; Kertesz, Nathalie ; Wang, Shungyou ; Li, Gang ; Gao, Jing ; Groszer, Matthias ; Martinez-Diaz, Hilda ; Rozengurt, Nora ; Thomas, George ; Liu, Xin ; Wu, Hong. / Genetic background controls tumor development in Pten-deficient mice. In: Cancer Research. 2006 ; Vol. 66, No. 13. pp. 6492-6496.
@article{00b8ea1308d7485bbd4a108b476bee91,
title = "Genetic background controls tumor development in Pten-deficient mice",
abstract = "PTEN is one of the most frequently mutated tumor suppressor genes in human cancers. Germ line mutations of PTEN have been detected in three rare autosomal-dominant disorders. However, identical mutations in the PTEN gene may lead to different symptoms that have traditionally been described as different disorders, such as Cowden disease, Lhermitte-Duclos disease, and Bannayan-Zonana syndromes. This lack of genotype-phenotype correlation prompted us to directly test the possible effects of genetic background or modifier genes on PTEN-controlled tumorigenesis using genetically engineered mouse models. In this study, we generated two animal models in which either exon 5 (Pten Δ5) or promoter to exon 3 (Pten-) of the murine Pten gene were deleted and compared phenotypes associated with individual mutations on two genetic backgrounds. We found that the onset and spectrum of tumor formation depend significantly on the genetic background but less on the type of mutation generated. Our results suggest that PTEN plays a critical role in cancer development, and genetic background may influence the onset, the spectrum, and the progression of tumorigenesis caused by Pten mutation.",
author = "Dan Freeman and Ralf Lesche and Nathalie Kertesz and Shungyou Wang and Gang Li and Jing Gao and Matthias Groszer and Hilda Martinez-Diaz and Nora Rozengurt and George Thomas and Xin Liu and Hong Wu",
year = "2006",
month = "7",
day = "1",
doi = "10.1158/0008-5472.CAN-05-4143",
language = "English (US)",
volume = "66",
pages = "6492--6496",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "13",

}

TY - JOUR

T1 - Genetic background controls tumor development in Pten-deficient mice

AU - Freeman, Dan

AU - Lesche, Ralf

AU - Kertesz, Nathalie

AU - Wang, Shungyou

AU - Li, Gang

AU - Gao, Jing

AU - Groszer, Matthias

AU - Martinez-Diaz, Hilda

AU - Rozengurt, Nora

AU - Thomas, George

AU - Liu, Xin

AU - Wu, Hong

PY - 2006/7/1

Y1 - 2006/7/1

N2 - PTEN is one of the most frequently mutated tumor suppressor genes in human cancers. Germ line mutations of PTEN have been detected in three rare autosomal-dominant disorders. However, identical mutations in the PTEN gene may lead to different symptoms that have traditionally been described as different disorders, such as Cowden disease, Lhermitte-Duclos disease, and Bannayan-Zonana syndromes. This lack of genotype-phenotype correlation prompted us to directly test the possible effects of genetic background or modifier genes on PTEN-controlled tumorigenesis using genetically engineered mouse models. In this study, we generated two animal models in which either exon 5 (Pten Δ5) or promoter to exon 3 (Pten-) of the murine Pten gene were deleted and compared phenotypes associated with individual mutations on two genetic backgrounds. We found that the onset and spectrum of tumor formation depend significantly on the genetic background but less on the type of mutation generated. Our results suggest that PTEN plays a critical role in cancer development, and genetic background may influence the onset, the spectrum, and the progression of tumorigenesis caused by Pten mutation.

AB - PTEN is one of the most frequently mutated tumor suppressor genes in human cancers. Germ line mutations of PTEN have been detected in three rare autosomal-dominant disorders. However, identical mutations in the PTEN gene may lead to different symptoms that have traditionally been described as different disorders, such as Cowden disease, Lhermitte-Duclos disease, and Bannayan-Zonana syndromes. This lack of genotype-phenotype correlation prompted us to directly test the possible effects of genetic background or modifier genes on PTEN-controlled tumorigenesis using genetically engineered mouse models. In this study, we generated two animal models in which either exon 5 (Pten Δ5) or promoter to exon 3 (Pten-) of the murine Pten gene were deleted and compared phenotypes associated with individual mutations on two genetic backgrounds. We found that the onset and spectrum of tumor formation depend significantly on the genetic background but less on the type of mutation generated. Our results suggest that PTEN plays a critical role in cancer development, and genetic background may influence the onset, the spectrum, and the progression of tumorigenesis caused by Pten mutation.

UR - http://www.scopus.com/inward/record.url?scp=33746154235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746154235&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-05-4143

DO - 10.1158/0008-5472.CAN-05-4143

M3 - Article

VL - 66

SP - 6492

EP - 6496

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 13

ER -